Barclays reissued their overweight rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Friday.

Other equities analysts have also issued reports about the stock. Berenberg Bank increased their price objective on shares of GlaxoSmithKline from GBX 1,780 ($22.71) to GBX 1,790 ($22.83) and gave the company a buy rating in a report on Wednesday, April 25th. Credit Suisse Group set a GBX 1,450 ($18.50) price objective on shares of GlaxoSmithKline and gave the company a neutral rating in a report on Monday, July 16th. UBS Group restated a buy rating and issued a GBX 1,700 ($21.69) price objective (up from GBX 1,600 ($20.41)) on shares of GlaxoSmithKline in a report on Monday, July 30th. Deutsche Bank set a GBX 1,525 ($19.45) price objective on shares of GlaxoSmithKline and gave the company a neutral rating in a report on Monday, July 9th. Finally, Kepler Capital Markets set a GBX 1,440 ($18.37) price objective on shares of GlaxoSmithKline and gave the company a neutral rating in a report on Monday, July 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of GBX 1,541.74 ($19.67).

GSK opened at GBX 1,550.80 ($19.78) on Friday. GlaxoSmithKline has a one year low of GBX 1,235.20 ($15.76) and a one year high of GBX 1,724.50 ($22.00).

The company also recently announced a dividend, which will be paid on Thursday, October 11th. Shareholders of record on Thursday, August 9th will be issued a GBX 19 ($0.24) dividend. The ex-dividend date of this dividend is Thursday, August 9th. This represents a yield of 1.23%.

In other news, insider Philip R. Hampton bought 2,810 shares of the business’s stock in a transaction on Wednesday, July 25th. The shares were bought at an average cost of GBX 1,557 ($19.86) per share, for a total transaction of £43,751.70 ($55,812.86). Also, insider David Redfern sold 1,925 shares of the stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.09), for a total transaction of £30,318.75 ($38,676.81). Over the last quarter, insiders acquired 2,826 shares of company stock worth $4,400,426.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Google Finance

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.